BriaCell Announces Phase 2 Data Showing Median Overall Survival Of 15.6 Months In Bria-IMT Study For Metastatic Breast Cancer, Comparing Favorably To 6.7-9.3 Months In Literature; No Drug-Related Discontinuations, And Ongoing Phase 3 Study...

Benzinga · Sep 11 20:28

BriaCell Announces Phase 2 Data Showing Median Overall Survival Of 15.6 Months In Bria-IMT Study For Metastatic Breast Cancer, Comparing Favorably To 6.7-9.3 Months In Literature; No Drug-Related Discontinuations, And Ongoing Phase 3 Study Investigating Bria-IMT

The above content is for informational or educational purposes only and does not constitute any investment advice related to Futu. Although we strive to ensure the truthfulness, accuracy, and originality of all such content, we cannot guarantee it.

BriaCell Announces Phase 2 Data Showing Median Overall Survival Of 15.6 Months In Bria-IMT Study For Metastatic Breast Cancer, Comparing Favorably To 6.7-9.3 Months In Literature; No Drug-Related Discontinuations, And Ongoing Phase 3 Study...

BriaCell Announces Phase 2 Data Showing Median Overall Survival Of 15.6 Months In Bria-IMT Study For Metastatic Breast Cancer, Comparing Favorably To 6.7-9.3 Months In Literature; No Drug-Related Discontinuations, And Ongoing Phase 3 Study Investigating Bria-IMT

Risk Disclaimer